Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Baudax Bio, Inc. BXRX
$0.67
-$0.01 (-1.38%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
2933910.00000000
-
week52high
50.00
-
week52low
0.70
-
Revenue
1269000
-
P/E TTM
0
-
Beta
1.56351300
-
EPS
-169.19000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 10:59
Описание компании
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 11 мая 2020 г. |
| Noble Capital Markets | Market Perform | Outperform | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| HENWOOD GERALDINE | A | 2427 | 1200 | 15 дек 2022 г. |
| Dilmore Jillian | A | 15738 | 15467 | 15 июн 2022 г. |
| Drechsler Andrew T | A | 41656 | 39473 | 15 июн 2022 г. |
| CHURCHILL WINSTON J | A | 46820 | 39473 | 15 июн 2022 г. |
| Baskies Arnold M | A | 41942 | 39473 | 15 июн 2022 г. |
| Ashton William | A | 42534 | 39473 | 15 июн 2022 г. |
| Weisman Wayne | A | 42900 | 39473 | 15 июн 2022 г. |
| HENWOOD GERALDINE | A | 49093 | 39473 | 15 июн 2022 г. |
| HENWOOD GERALDINE | A | 821168 | 821168 | 22 дек 2021 г. |
| HENWOOD GERALDINE | D | 336716 | 18636 | 15 дек 2021 г. |
Новостная лента
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
MarketBeat
26 янв 2023 г. в 04:01
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. While the interim positive outcome is based on a 20-patient group, it expects to complete the phase 2 trial with 80 patients by the end of the first quarter of 2023.
Why Is Baudax Bio (BXRX) Stock Up 50% Today?
InvestorPlace
24 янв 2023 г. в 10:58
What caused Baudax Bio (NASDAQ: BXRX ) stock to double earlier today? The catalyst was undoubtedly this morning's announcement concerning a Phase 2 clinical trial of Baudax Bio's novel product, BX1000.
Penny Stocks Risk Management: 3 Tips and Tricks
PennyStocks
30 дек 2022 г. в 06:00
Use these penny stocks risk management tips for trading The post Penny Stocks Risk Management: 3 Tips and Tricks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The 7 Most Sold-Off Stocks of 2022
InvestorPlace
24 дек 2022 г. в 16:27
With a contentious time in 2022 coming to a close, it may be helpful to look back and consider the most sold-off stocks last year. Similar to learning from prior mistakes, investors may be able to garner lessons from the worst-hit market ideas.
Why Is Baudax Bio (BXRX) Stock Up 46% Today?
InvestorPlace
09 дек 2022 г. в 09:48
Baudax Bio (NASDAQ: BXRX ) stock is rocketing higher on Friday after the pharmaceutical company initiated a Phase 2 clinical trial of BX1000. BX1000 is the company's drug candidate for neuromuscular blockade in patients undergoing elective surgery.